1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. タイプ別スニペット
3.2. 治療タイプ別スニペット
3.3. 患者タイプ別スニペット
4. ダイナミクス
4.1. 影響因子
4.1.1. 推進要因
4.1.1.1. 悪性胸膜中皮腫（MPM）の有病率の上昇
4.1.1.2. 製品開発活動および規制当局による承認の増加
4.1.2. 阻害要因
4.1.2.1. 治療費の高騰
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. 価格分析
5.3. パイプライン分析
5.4. 規制分析
5.5. アンメット・ニーズ
5.6. PESTEL分析
5.7. 特許分析
5.8. SWOT分析
5.9. 疫学
6. タイプ別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率分析（%）, タイプ別
6.1.2. 市場魅力度指数（タイプ別
6.2. 上皮
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 肉腫性
6.4. 混合型（二相性）
7. 治療タイプ別
7.1. はじめに
7.1.1. 治療タイプ別市場規模分析および前年比成長率分析（%） 7.1.2.
7.1.2. 市場魅力度指数（治療タイプ別
7.2. 化学療法
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.2.3. シスプラチン
7.2.4. ペメトレキセド
7.2.5. その他
7.3. 免疫療法
7.3.1. ペムブロリズマブ
7.3.2. ニボルマブ
7.3.3. イピリムマブ
7.4. 標的療法
7.5. 放射線療法
7.6. 3モダリティ療法
7.7. 手術療法
7.7.1. 胸膜外肺切除術（EPP）
7.7.2. 拡大胸膜切除/剥皮術（eP/D）
8. 患者タイプ別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（%）、患者タイプ別
8.1.2. 市場魅力度指数（患者タイプ別
8.2. 男性*市場
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 女性
9. 地域別
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析（%）, タイプ別
9.2.4. 市場規模分析およびYoY成長率分析(%)、治療タイプ別
9.2.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
9.2.6. 市場規模分析および前年比成長率分析（%）, 国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. 市場規模分析および前年比成長率分析（%）, タイプ別
9.3.4. 市場規模分析およびYoY成長率分析(%)、治療タイプ別
9.3.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
9.3.5.1. 市場規模分析および前年比成長率分析（%）, 国別
9.3.5.2. ドイツ
9.3.5.3. イギリス
9.3.5.4. フランス
9.3.5.5. イタリア
9.3.5.6. スペイン
9.3.5.7. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. 市場規模分析および前年比成長率分析（%）, タイプ別
9.4.4. 市場規模分析およびYoY成長率分析(%)、治療タイプ別
9.4.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
9.4.5.1. 市場規模分析および前年比成長率分析（%）, 国別
9.4.5.2. ブラジル
9.4.5.3. アルゼンチン
9.4.5.4. その他の南米地域
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. 市場規模分析および前年比成長率分析（%）, タイプ別
9.5.4. 市場規模分析およびYoY成長率分析（%）, 治療タイプ別
9.5.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
9.5.6. 市場規模分析および前年比成長率分析（%）, 国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. 市場規模分析および前年比成長率分析（%）, タイプ別
9.6.4. 市場規模分析およびYoY成長率分析（%）, 治療タイプ別
9.6.5. 市場規模分析および前年比成長率分析（%）, 患者タイプ別
10. 競合情勢
10.1. 競合シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. Eli Lilly and Company*
11.1.1. 会社概要
11.1.2. 製品ポートフォリオと内容
11.1.3. 財務概要
11.1.4. 主な展開
11.2. Bristol-Myers Squibb Company.
11.3. Accord Healthcare US.
11.4. Merck & Co., Inc.
11.5. Novartis AG
11.6. Pfizer Inc.
11.7. MEDYRA PHARMACEUTICAL
11.8. Teva Pharmaceuticals USA, Inc.
11.9. Hikma Pharmaceuticals PLC
11.10. AstraZeneca (*リストは除外)
12. 付録
12.1. アストラゼネカについて
12.2. お問い合わせ
The Global Malignant Pleural Mesothelioma Treatment Market reached US$ 387.73 million in 2023 and is expected to reach US$ 649.83 million by 2031, growing at a CAGR of 6.8% during the forecast period 2024-2031.
Malignant pleural mesothelioma is a very rare and aggressive form of cancer in the membrane covering the lungs and the inner side of the ribs. This neoplasm is seen in patients with occupational exposure to asbestos and the latent period between exposure and diagnosis ranges from 20 years to 40 years. MPM accounts for nearly 80% to 90% of total mesothelioma diagnoses. The common symptoms of MPM include chest pain, dry cough, shortness of breath etc. The prognosis of MPM is poor with a survival time of 12-18 months.
Market Dynamics: Drivers
Rising product development activities and regulatory approvals
Malignant pleural mesothelioma (MPM) is a rare cancer that occurs in a population with asbestos exposure. The latency period between exposure and presentation is nearly 30 years on average. Although the condition is rare with poor prognosis, several global manufacturers are developing novel drugs and some are striving to expand the applications of approved immunotherapies to MPM. These product development activities and subsequent approvals by the regulatory bodies act as a major driver for market growth in the forecast period.
For instance, on September 18, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy. Sold under the brand name KEYTRUDA developed by Merck is an immunotherapy drug and is currently the top-selling brand globally.
Moreover, AstraZeneca is conducting phase 3 clinical trials for Volrustomig an immunotherapy drug for unresectable pleural mesothelioma. The trial is evaluating the efficacy of Volrustomig + Carboplatin + Pemetrexed versus the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab (approved immunotherapies). The study is anticipated to be finished in the first quarter of 2028.
Restraints
The market for malignant pleural mesothelioma (MPM) treatments is restrained by several factors such as side effects associated with chemotherapy and immunotherapy, poor prognosis with the existing and novel treatment modalities, high cost of treatment, and supply chain discrepancies of chemotherapy drugs.
Market Segment Analysis
The global malignant pleural mesothelioma (MPM) treatment market is segmented based on type, treatment type, patient type, and region.
Immunotherapy in the treatment type segment accounted for approximately 54.4% of the global malignant pleural mesothelioma (MPM) treatment market share.
Platinum-based chemotherapy and tri-modality therapies (combination of surgery, chemotherapy, and radiation therapy) were the two major treatment modalities considered as gold standard for malignant pleural mesothelioma. However, these gold-standard therapies have several limitations and drawbacks with poor prognosis as a major one.
On the other hand, immunotherapy has evolved evidently as a revolutionary therapeutic option for cancer. Several drugs were developed and received approval for more prevalent types of cancer. Recently, the applications of immunotherapy drugs have expanded to malignant pleural mesothelioma with the approval of nivolumab plus ipilimumab in October 2020, as a first-line treatment for unresectable malignant pleural mesothelioma. Following the approval of these drugs, KEYTRUDA recently received FDA approval in September 2024 for use as a first-line treatment in combination with pemetrexed and platinum.
Even if the treatment rate is lower for immunotherapy drugs, they reflect an overall higher market share due to their high cost. Moreover, there are several immunotherapy drugs in the pipeline, which have the scope to make a market entry in the near future. Hence the market for immunotherapy in the treatment type segment is anticipated to experience a significant growth rate in the forecasted period.
Market Geographical Share
North America dominates the global malignant pleural mesothelioma (MPM) treatment market with a share of 42.3% in 2023
North America dominates the global malignant pleural mesothelioma (MPM) treatment market due to its advanced healthcare infrastructure and facilities, easy accessibility to a variety of treatments, availability of branded drugs offered by global pharmaceutical industry leaders, etc.
The United States is well known for its advanced healthcare industry. The higher per-capita income, expenditure, and investments in the healthcare industry and stringent yet favorable regulatory policies attract the manufacturers to develop novel therapies and launch them first in the country. Patients in the U.S. are at the forefront of receiving these advanced therapies, as they are backed by favorable reimbursement policies. For instance, the combination immunotherapy Opdivo+Yervoy by Bristol-Myers Squibb Company was first made available in the U.S., similar to the drug Keytruda by Merck. These drugs majorly generate their revenue in the North American region. Moreover, Eli Lilly generated 33.5% of Alimta (pemetrexed) revenue in 2023 from the U.S., which is far higher than any other country across the globe. Alimta is one of the most commonly used chemotherapy drugs for malignant pleural mesothelioma.
Hence, considering these factors, along with the epidemiological data and sales figures of other product categories by all market players, North America is designated as a dominant region in the global market.
Market Segmentation
By Type
Epithelial
Sarcomatous
Mixed (Biphasic)
By Treatment Type
Chemotherapy
Cisplatin
Pemetrexed
Others
Immunotherapy
Pembrolizumab
Nivolumab
Ipilimumab
Targeted Therapy
Radiation Therapy
Tri-Modality Therapy
Surgery
Extra Pleural Pneumonectomy (EPP)
Extended Pleurectomy/Decortication (eP/D)
By Patient Type
Male
Female
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major players in the malignant pleural mesothelioma (MPM) treatment market include Eli Lilly and Company, Bristol-Myers Squibb Company., Accord Healthcare US., Merck & Co., Inc., Novartis AG, Pfizer Inc., MEDYRA PHARMACEUTICAL, Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, and AstraZeneca among others.
Why Purchase the Report?
To visualize the global malignant pleural mesothelioma (MPM) treatment
Market Segmentation based on type, treatment type, patient type, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of malignant pleural mesothelioma (MPM) treatment market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The global malignant pleural mesothelioma (MPM) treatment market report would provide approximately 62 tables, 54 figures, and 212 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment Type
3.3. Snippet by Patient Type
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of malignant pleural mesothelioma (MPM)
4.1.1.2. Rising product development activities and regulatory approvals
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Pipeline Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
5.9. Epidemiology
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Epithelial*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Sarcomatous
6.4. Mixed (Biphasic)
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Chemotherapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Cisplatin
7.2.4. Pemetrexed
7.2.5. Others
7.3. Immunotherapy
7.3.1. Pembrolizumab
7.3.2. Nivolumab
7.3.3. Ipilimumab
7.4. Targeted Therapy
7.5. Radiation Therapy
7.6. Tri-Modality Therapy
7.7. Surgery
7.7.1. Extra Pleural Pneumonectomy (EPP)
7.7.2. Extended Pleurectomy/Decortication (eP/D)
8. By Patient Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
8.1.2. Market Attractiveness Index, By Patient Type
8.2. Male*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Female
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.3.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.2. Germany
9.3.5.3. UK
9.3.5.4. France
9.3.5.5. Italy
9.3.5.6. Spain
9.3.5.7. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.4.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.2. Brazil
9.4.5.3. Argentina
9.4.5.4. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Eli Lilly and Company*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Bristol-Myers Squibb Company.
11.3. Accord Healthcare US.
11.4. Merck & Co., Inc.
11.5. Novartis AG
11.6. Pfizer Inc.
11.7. MEDYRA PHARMACEUTICAL
11.8. Teva Pharmaceuticals USA, Inc.
11.9. Hikma Pharmaceuticals PLC
11.10. AstraZeneca (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us
❖ 世界の悪性胸膜中皮腫（MPM）治療市場に関するよくある質問(FAQ) ❖
・悪性胸膜中皮腫（MPM）治療の世界市場規模は？
→DataM Intelligence社は2023年の悪性胸膜中皮腫（MPM）治療の世界市場規模を3億8,773万米ドルと推定しています。
・悪性胸膜中皮腫（MPM）治療の世界市場予測は？
→DataM Intelligence社は2031年の悪性胸膜中皮腫（MPM）治療の世界市場規模を6億4,983万米ドルと予測しています。
・悪性胸膜中皮腫（MPM）治療市場の成長率は？
→DataM Intelligence社は悪性胸膜中皮腫（MPM）治療の世界市場が2024年～2031年に年平均6.8%成長すると予測しています。
・世界の悪性胸膜中皮腫（MPM）治療市場における主要企業は？
→DataM Intelligence社は「Eli Lilly and Company, Bristol-Myers Squibb Company., Accord Healthcare US., Merck & Co., Inc., Novartis AG, Pfizer Inc., MEDYRA PHARMACEUTICAL, Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, and AstraZeneca など ...」をグローバル悪性胸膜中皮腫（MPM）治療市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
